Elite in Melanoma

Joseph J. Sacco

Liverpool, ENG, GB 
Elite in Melanoma
Liverpool, ENG, GB 
OverviewLocationsClinical Research

Overview

Joseph Sacco practices in Liverpool, United Kingdom. Mr. Sacco is rated as an Elite expert by MediFind in the treatment of Melanoma. His top areas of expertise are Metastatic Uveal Melanoma, Uveal Melanoma, Melanoma, and Melanoma of the Eye.

His clinical research consists of co-authoring 56 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 31 articles and participated in 4 clinical trials in the study of Melanoma.

Gender
Male

Locations

Liverpool, ENG, United Kingdom
Other Locations
Bebington, ENG, United Kingdom
Wirral, ENG, United Kingdom
Mount Vernon Cancer Centre, Liverpool And Immunocore, Abingdon, ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors [IGNYTE]
An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors [IGNYTE]
Enrollment Status: Active_not_recruiting
Publish Date: December 17, 2025
Intervention Type: Biological
Study Drugs: RP1, Nivolumab
Study Phase: Phase 2
An Open-Label, Multicenter, Phase 1 Study of RP3 as a Single Agent and in Combination With PD-1 Blockade in Patients With Solid Tumors
An Open-Label, Multicenter, Phase 1 Study of RP3 as a Single Agent and in Combination With PD-1 Blockade in Patients With Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: September 09, 2025
Intervention Type: Biological
Study Drug: RP3 Genetically-Modified Herpes Simplex Virus 1
Study Phase: Phase 1
A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared With Investigator Choice in HLA-A*0201 Positive Patients With Previously Untreated Advanced Uveal Melanoma
A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared With Investigator Choice in HLA-A*0201 Positive Patients With Previously Untreated Advanced Uveal Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: August 01, 2025
Intervention Type: Biological, Drug
Study Drugs: IMCgp100, Dacarbazine, Ipilimumab, Pembrolizumab
Study Phase: Phase 2
NICO - CA209-891: Neoadjuvant and Adjuvant Nivolumab as Immune Checkpoint Inhibition in Oral Cavity Cancer
NICO - CA209-891: Neoadjuvant and Adjuvant Nivolumab as Immune Checkpoint Inhibition in Oral Cavity Cancer
Enrollment Status: Completed
Publish Date: February 25, 2025
Intervention Type: Biological
Study Drug: Nivolumab
Study Phase: Phase 2
A Phase 1/2 First-in-human Study of the Safety and Efficacy of IMC-C103C as Single Agent and in Combination With Atezolizumab in HLA-A*0201-positive Patients With Advanced MAGE-A4-positive Cancer
A Phase 1/2 First-in-human Study of the Safety and Efficacy of IMC-C103C as Single Agent and in Combination With Atezolizumab in HLA-A*0201-positive Patients With Advanced MAGE-A4-positive Cancer
Enrollment Status: Withdrawn
Publish Date: October 18, 2024
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase I Trial of WEE1 Inhibition with Chemotherapy and Radiotherapy As Adjuvant Treatment, and a Window of Opportunity Trial with Cisplatin in Patients with Head and Neck Cancer
A Phase I Trial of WEE1 Inhibition with Chemotherapy and Radiotherapy As Adjuvant Treatment, and a Window of Opportunity Trial with Cisplatin in Patients with Head and Neck Cancer
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug, Radiation
Study Phase: Phase 1
A Single-arm, Multi-Center, Open-Label Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment in Patients With Hepatic-Dominant Ocular Melanoma
A Single-arm, Multi-Center, Open-Label Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment in Patients With Hepatic-Dominant Ocular Melanoma
Enrollment Status: Completed
Publish Date: December 21, 2023
Intervention Type: Combination product
Study Drug: Melphalan/Hepatic Device System
Study Phase: Phase 3
A Phase I/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Using the Intra-patient Escalation Dosing Regimen in Patients With Advanced Uveal Melanoma
A Phase I/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Using the Intra-patient Escalation Dosing Regimen in Patients With Advanced Uveal Melanoma
Enrollment Status: Completed
Publish Date: March 21, 2023
Intervention Type: Drug
Study Drug: IMCgp100
Study Phase: Phase 1/Phase 2
View 7 Less Clinical Trials

56 Total Publications

RP1 Combined With Nivolumab in Advanced Anti-PD-1-Failed Melanoma (IGNYTE).
RP1 Combined With Nivolumab in Advanced Anti-PD-1-Failed Melanoma (IGNYTE).
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 08, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Sacco's expertise for a condition
ConditionClose
View All 8 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile